S.Amdt. 1772Senate117th Congress (2021-2023)2nd degree
S.Amdt. 1772
Sponsored by
Sen. James Lankford (R-OK)
Submitted May 20, 2021
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Floor
Latest Action
Senate amendment submitted
May 20, 2021
Text
Submitted
SA 1772. Mr. LANKFORD (for himself and Mr. Tillis) submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. Schumer to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows: At the appropriate place, insert the following: SEC. ___. CONGRESSIONAL REVIEW PROCEDURES FOR WAIVER OF OBLIGATIONS WITH RESPECT TO VACCINES OR OTHER BIOTECHNOLOGY COMMODITIES UNDER THE AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS. Section 122 of the Uruguay Round Agreements Act (19 U.S.C. 3532) is amended by adding at the end the following: ``(e) Approval by Congress of Certain Waivers With Respect to Vaccines or Other Biotechnology Commodities.-- ``(1) In general.--A waiver described in paragraph (2) granted under subsection (b)(2) shall not enter into force with respect to the United States, and no funds shall be used by the Secretary of Commerce, the Secretary of Health and Human Services, or the Trade Representative to implement the terms of that waiver, unless-- ``(A) the President submits the text of the proposed waiver agreement to the appropriate congressional committees; and ``(B) a joint resolution is enacted approving the waiver not later than 180 days after the later of the date on which-- ``(i) the report under subsection (c)(2)(A) with respect to that waiver is submitted; or ``(ii) the text of the proposed waiver agreement under subparagraph (A) is submitted. ``(2) Waiver described.--A waiver described in this paragraph is a waiver of certain provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights referred to in section 101(d)(15) for a vaccine or other biotechnology commodity. ``(3) Introduction and referral of joint resolution.--A joint resolution under paragraph (1)(B) may be introduced by any member of Congress and shall be referred-- ``(A) in the Senate, to the Committee on Finance; and ``(B) in the House of Representatives, to the Committee on Ways and Means.''. ______